257 related articles for article (PubMed ID: 30045109)
1. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
Nayyar PM; Chang ALS; Sarin K; Ratner D
Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
[No Abstract] [Full Text] [Related]
2. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
3. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
[TBL] [Abstract][Full Text] [Related]
4. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
Powell EM; Stratton JS; Shendrik I; Blalock TW
Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
[No Abstract] [Full Text] [Related]
5. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
6. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
7. Treatment of locally advanced basal cell carcinoma with vismodegib.
Moreiras Arias N; Vázquez Veiga H; Sánchez-Aguilar D
Med Clin (Barc); 2023 May; 160(9):413-414. PubMed ID: 36646552
[No Abstract] [Full Text] [Related]
8. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
Kaehler KC; Gutzmer R; Egberts F; Hauschild A
J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
[No Abstract] [Full Text] [Related]
9. Vismodegib (Erivedge) for basal cell carcinoma.
Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
[No Abstract] [Full Text] [Related]
10. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
[No Abstract] [Full Text] [Related]
11. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
[No Abstract] [Full Text] [Related]
12. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature.
Viscusi KS; Hanke CW
J Drugs Dermatol; 2015 Sep; 14(9):956-62. PubMed ID: 26355613
[TBL] [Abstract][Full Text] [Related]
13. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases.
Bancalari B; Llombart B; Serra-Guillén C; Bernia E; Requena C; Nagore E; Traves V; Calomarde L; Diago A; Guillén C; Sanmartín O
Am J Dermatopathol; 2019 Oct; 41(10):711-717. PubMed ID: 31436575
[TBL] [Abstract][Full Text] [Related]
14. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
[TBL] [Abstract][Full Text] [Related]
15. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
16. Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib.
Smith SDB; Clarke CN; Clark MA; Harker-Murray AK; Sokumbi O
Am J Dermatopathol; 2021 Aug; 43(8):585-587. PubMed ID: 33534208
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
18. Reversible cutaneous side effects of vismodegib treatment.
Kwong B; Danial C; Liu A; Chun KA; Chang AL
Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
[No Abstract] [Full Text] [Related]
19. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
[No Abstract] [Full Text] [Related]
20. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
[No Abstract] [Full Text] [Related]
[Next] [New Search]